Due to the resurgence of tuberculosis and the emergence of multidrug-resistant strains, fluoroquinolones (FQ) are being used in selected tuberculosis patients, but FQ-resistant strains of Mycobacterium tuberculosis have rapidly begun to appear. The mechanisms involved in FQ resistance need to be elucidated if the effectiveness of this class of antibiotics is to be improved and prolonged. By using the rapid-growing Mycobacterium smegmatis as a model genetic system, a gene was selected that confers low-level FQ resistance when present on a multicopy plasmid. This gene, lfrA, encodes a putative membrane efflux pump of the major facilitator family, which appears to recognize the hydrophilic FQ, ethidium bromide, acridine, and some quaternary ammonium compounds. It is homologous to qacA from Staphylococcus aureus, tcmA, ofStreptomyces glaucescens, and actII and mmr, both from Streptomyces coelicoler. Increased expression of lfrA augments the appearance of subsequent mutations to higher-level FQ resistance.
The worldwide reemergence of tuberculosis as a major public health problem has been accompanied by an ominous increase in multidrug resistant strains (1) . This increase has stimulated an intense search for new antimycobacterial agents, but at present only one additional class of drugs, the fluoroquinolones (FQ), has been added to the traditional anti-tuberculosis armamentarium (2) . Introduced into clinical practice in the 1980s, the FQ were initially active against many pathogens (3), but their use has been limited by the rapid appearance of resistance in a large percentage of clinical isolates, especially in Staphylococcus aureus and Pseudomonas aeruginosa (41, 42) . The therapeutic use of the FQ in tuberculosis began only within the past 3-4 years, and they are generally reserved for infections resistant to other agents. However, most FQ are only moderately active against the mycobacteria, and unfortunately, FQ-resistant (FQr) clinical isolates of Mycobacterium tuberculosis have already appeared (4, 5) . If more can be learned about what determines the effectiveness of a particular FQ against the mycobacteria and the mechanisms by which resistance develops, new agents or strategies may be designed that can prevent or circumvent this resistance.
The principal targets of the FQ are bacterial type II topoisomerases, including both the bacterial DNA gyrase, an essential type II topoisomerase that introduces supercoils into the DNA chromosome (6) , and the highly homologous topoisomerase IV, which deconcatenates the chromosome after DNA replication (7, 8) . Mutations in a particular region of gyrA, which encodes the gyrase A subunit, have been associated with moderate-to-high level [>5x minimal inhibitory concentration (MIC)] FQ resistance in many species of bacteria, including M. tuberculosis (5) , and similar mutations have been found in the homologous region of topoisomerase IV (9, 10 ). Mutations conferring low-level resistance have also been
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found in gyrB (11) encoding the B subunit of the DNA gyrase, and the most highly resistant strains often contain mutations in several sites (12) , as well as double gyrA mutations (13) . The principal candidates for nontarget (non-type II topoisomerase) mutations are genes that control the intracellular concentration of the FQ (14) . These include the genes for membrane porins, such as ompF (15, 16) , presumably mediating entry of the drug into the bacteria, and genes for membrane efflux pumps, such as norA (17, 18) , that extrude drug out of the bacteria in exchange for protons (19) . Many of the described mutations do not alter the amino acid sequence of these membrane proteins but rather affect their expression, by either gene amplification (20) , promoter-up mutations (21) , or mutations in regulatory loci such as mar (22) , sox (23) , or pqr (24) .
In this report, using the rapid growing Mycobacterium smegmatis as a model genetic system (25) Construction of Genomic Libraries and Isolation of lfrA. Genomic DNA was isolated from Cip-resistant (Cipr) strain mc2552 as described (25) . After a partial digestion with Msp I, 3-to 6-kb fragments were ligated into the Cla I site of vector pYUB53 (25) , transformed into E. coli DH5a, and plated on LB Tet. Colonies were pooled, and plasmid DNA was isolated (27) and electroporated into mc2155 (25) , which was then plated on 7H11 plates with Cip at 1 ,ug/ml and Tet at 2.5 jig/ml. Plasmid pMN1 was isolated from Tet-resistant (Tetr) Cipr M. smegmatis colonies and transformed into E. coli. Plasmid DNA for analysis, cloning, and sequencing was isolated from E. coli (27) .
Subcloning and Sequencing of lfrA. Clone pMN1 was cut with various enzymes to generate a restriction map, and fragments were subcloned into vectors pMV203 (26) (pSB51-pSB53) or pMD31 (28) (Fig. 1) . Miniprep DNA of the subclones was electroporated into mc2155, and kanamycinresistant (Kanr) colonies were tested for Cip resistance. The insert from pSB51, which conferred Cip resistance, was subcloned into vectors pUC118 and pUC119, and serial deletions were created by using Promega Erase-a-Base. Helper phage M13K07 was used to obtain single-stranded DNA for sequencing (27) , and double-stranded DNA was prepared (27) (5) . On the basis of the M. smegmatisgyrA sequence obtained from the hybridizing clones, primers were constructed and used as described (5) To obtain the minimum fragment of DNA conferring Cip resistance, pMN1 was digested with several restriction enzymes and subcloned into vector pMV203 (Fig. 1) . The smallest fragment conferring Cipr colonies was found to be the 2.3-kb insert in pSB51, although the level of resistance (Cip at 2 ,ug/ml) was slightly less than that conferred by pMN1 (Cip at 3 ,tg/ml). It is notable that all plasmid constructions conferred much lower-level resistance to Cip than seen in the original mutant strain mc2552, which grew well on plates with 16 ,ug/ml.
Sequence oflfrA. Sequence analysis showed that the insert of pSB51 contained an open reading frame of 1674 bp with no obvious consensus promoter sequence (Fig. 1 ). Similarity searches with BLASTX revealed homology to the membrane efflux pumps of the major facilitator family. On the basis of this homology and the location of a putative ribosome-binding site, the methionine shown in Fig. 1 (32) , and mmr (33) , (34/58, 32/57, and 27/52% identity/% similarity, respectively) all from streptomyces (Fig. 2 ). Like these, the predicted M. smegmatis protein appears to have 14 hydrophobic, membrane-spanning regions. The gene was named ifrA, for low-level FQ resistance.
LfrA on pMN1 Is Expressed from the Kan Promoter.
Initially, it was expected that IfrA from strain mc2552 would contain a mutation changing its specificity. However, the membrane efflux pumps norA (21) and bmr (20) confer FQ resistance when their expression is increased, and emrB (35) was found on the basis of a multicopy effect, so it was possible that IfrA also conferred resistance solely because of its presence on a multicopy plasmid. To test this hypothesis, a WT IfrA gene was selected by hybridization to a cosmid library of Cip-sensitive M. smegmatis and subcloned into pMD31 to create pIV703 (Fig. 1) . The presence of the WT IfrA gene on pIV703 in mc2155 confers resistance to Cip at 1 ,ug/ml, suggesting a multicopy effect, but the level of resistance was less than that seen with pMN1 (3 ,ug/ml).
To define the basis for the higher resistance conferred by pMNI, a series of plasmids were constructed to compare the ifrA genes on pMNI and pIV703 (Fig. 1) . When the IfrA protein-coding region from pIV703 was ligated to the upstream region from plasmid pMN1, the resulting plasmid, pIV732, conferred resistance to Cip at 2 ,ug/ml. This result suggested that IfrA expression on pMN1 was driven by the strong Kan promoter on parent vector pYUB53; this is possible because pMN1 was constructed by cloning into a Cla I site in vector pYUB53, which lies within the kanamycin resistance (aph) gene. Examination of the ligated sequence shows the Aph protein to be in the same reading frame as LfrA, with one stop codon, UGA, at the beginning of the cloned insert. Expression from the Kan promoter seems likely because resistance is reduced to Cip at 1 j,g/ml when the entire vector segment (pIV725), or merely the promoter of the aph gene, is removed (pIV743). Therefore the increased level of Cip resistance conferred by pMN1 is not due to a mutation in either the IfrA protein coding or upstream segments but rather to increased expression from the aph promoter.
mc2551 Contains a Mutation in GyrA. As mentioned above, the original mutant strain mc2552 grew on plates with Cip at 16 ,ug/ml, but mc2155-containing pMN1 will grow only on plates containing no more than 2-3 jig/ml. It QacA is a plasmid-based efflux pump found in S. aureus strains resistant to disinfectants (30) . Mmr (33) , ActIl (31) , and TcmA (32) are export pumps associated with the streptomyces biosynthetic gene clusters producing the antibiotics methylenomycin, actinorhodin, and tetracenomycin, respectively. Amino acid identity with LfrA is indicated with a period (.), residues identical among all five proteins are underscored with an asterisk, and gaps are shown with hyphens. least a 2-to 4-fold increase in resistance to the hydrophilic FQs Cip, ofloxacin, levofloxacin, and DU-6859-a. However, pMN1 does not confer resistance to the hydrophobic FQs sparfloxacin and nalidixic acid (Tables 1 and 2 ). (20, 35) (Table  2 ). They were found to increase the MIC 2-to 4-fold to ethidium bromide, acriflavine, and CTAB. LfrA on pIV703 also increased resistance to ethidium bromide 4-fold (data not shown). These studies were then repeated in the presence of CCCP, an energy uncoupler that has been shown to inhibit the action of other efflux pumps (19, 20) . CCCP reduced the MIC for all drugs tested, suggesting that the MICs of these compounds are at least partially determined by Lfr and other proton antiporter efflux pumps. At 10 jig/ml, CCCP selections on increasing Cip concentrations. The gyrA mutation apparently occurred in one of these steps, but the mutations responsible for the other steps and the contribution of the gyrA mutation alone are unclear. Although we initially expected that one of these steps was a mutation to increase the expression of IfrA, our chimeric plasmid studies suggest there is no mutation in the region of lfrA contained on pMN1. It is possible, however, that mc2552 has a mutation in another effux pump, distinct from LfrA, or in a regulatory locus such as mar (22) sox (23), orpqr (24) , that would increase the expression of either LfrA or the relevant efflux pump.
Increased expression of IfrA seems to raise the frequency of subsequent mutations to higher levels of resistance; this could provide a model of how strains become progressively more resistant. Increased expression of the efflux pump may permit the bacteria to survive at low Cip concentrations and subsequently allow selection for a second mutation to an increased level of resistance, at a frequency that is substantially higher than that of selecting both mutations in a single step (37) . If the mutation frequency is augmented by the mutagenic effect described for the FQ (38) , one would also expect other, unrelated mutations to be more frequent, but this hypothesis has not been studied.
While the factors that determine a bacteria's intrinsic MIC for a particular FQ are poorly defined, they may include its permeation into the bacteria and its affinity as a substrate for the efflux pumps present in the organism (14, 39) . The mycobacteria are likely to have other efflux pumps besides Lfr, including perhaps one more homologous to EmrB, which could extrude the hydrophobic FQ. It is possible, however, that the greater effectiveness of Lfr against hydrophilic compounds is not due to specificity of the pump but rather reflects the greater permeability of hydrophobic compounds through the lipid-rich mycobacterial cell wall (43) . As the steady-state intracellular level of a drug is determined by the balance between influx and efflux, an efflux mechanism would be less effective against a drug that can penetrate the cell wall with a reasonably (40) high influx rate.
Finally, one would like to know whether an lfrA-mediated FQr mechanism could be relevant to the pathogenic mycobacteria. Hybridizations to genomic DNA suggest that a gene homologous to ifrA exists in M. tuberculosis and Mycobacterium avium (unpublished results) . Efflux pumps such as LfrA could influence the MIC and, with increased expression, confer resistance to antibiotics. If multidrug resistance continues to emerge as a problem in the control of tuberculosis, it will be important to elucidate and characterize the multidrug resistance pumps of M. tuberculosis that affect MIC and therapeutic efficacy of the FQ and other chemotherapeutic agents.
